سعر ليوفيرس 75 وحدة فيال 2024

Luveris 75 IU lutropin alfa (recombinant human LH) powder for injection, 1 vial, by Merck Serono (listed in Egypt).

• In association with an FSH preparation, stimulation of follicular development in adult women with severe LH and FSH deficiency.Population: Adult womenEuropean Medicines Agency (EPAR)

• Very common/common: headache, abdominal pain, nausea, vomiting, diarrhoea, mild to moderate OHSS, ovarian cyst, breast pain, pelvic pain and injection-site reactions. Very rare: hypersensitivity reactions and thromboembolism.International label, same formulation · European Medicines Agency (EPAR)

• Hypersensitivity to gonadotropins or excipients; tumours of the hypothalamus or pituitary; ovarian enlargement or cyst not due to polycystic ovarian disease; gynaecological haemorrhage of unknown origin; ovarian, uterine or mammary carcinoma; conditions where a normal pregnancy cannot be obtained (primary ovarian failure, malformations of sexual organs, fibroid tumours incompatible with pregnancy).International label, same formulation · European Medicines Agency (EPAR)

• Ovarian hyperstimulation syndrome (OHSS) and ovarian torsion: monitor with ultrasound and oestradiol; withhold hCG if excessive response.International label, same formulation · European Medicines Agency (EPAR)
• Multiple pregnancy, pregnancy loss, ectopic pregnancy and congenital malformations are more frequent after assisted reproduction.International label, same formulation · European Medicines Agency (EPAR)
• Thromboembolic events: weigh risks in women with risk factors; porphyria may be precipitated; reproductive-system neoplasms have been reported after infertility treatment.International label, same formulation · European Medicines Agency (EPAR)

• Other medicinal products (mixing)No interaction studies performed. Must not be mixed with other medicinal products in the same syringe except follitropin alfa.European Medicines Agency (EPAR)

• Not indicated during pregnancy; no teratogenic risk has been reported after controlled ovarian stimulation in limited data.International label, same formulation · European Medicines Agency (EPAR)
• Not indicated during breastfeeding.International label, same formulation · European Medicines Agency (EPAR)

• Lutropin alfa: Recombinant human LH produced in CHO cells; with FSH it stimulates ovarian follicular development and steroidogenesis (androgen supply for oestradiol production) in LH-deficient women (EU SmPC).